Released Nov 7, 2018, before the open
10-Q filed Nov 7, 2018, 38 days after period end · 0001144204-18-057990
Q3 2018 · 10-Q
Revenue$663.00K$663.00K −91.2% vs Q3 2017−66.9% vs Q2 2018
Net Income-$5.32M-$5.32M N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.40-$0.40 N/M vs Q3 2017N/M vs Q2 2018
Gross Profit-$1,254,000N/M
Operating Income-$3,741,000N/M
Operating Cash Flowderived$13,639,000N/M
Free Cash Flowderived$13,535,000N/M
Margins · derived
Gross margin-189.1%−208.5 pt vs Q3 2017
Operating margin-564.3%−461.1 pt vs Q3 2017
Net margin-802.7%−650.7 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $663.00K | $7.53M | $4.67M | $1.34M |
| Net Income | -$5.32M | -$11.44M | -$7.29M | -$3.82M |
| EPS Diluted | -$0.40 | -$0.09 | -$0.07 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR